Bristol Myers Ends Blood Cancer Drug Deal With Cell Therapy Maker Cellares
What's Happening
Bristol Myers Squibb (BMS) has ended its partnership with cell-therapy startup Cellares to manufacture its personalized blood-cancer treatment Breyanzi at commercial scale.
BMS said Cellares' Cell Shuttle manufacturing platform did not meet the requirements needed to produce Breyanzi at commercial scale. The decision affects the specific Breyanzi manufacturing arrangement and does not end BMS's broader relationship with cell therapy. (Reuters)
The companies had signed the original agreement in 2024, with the deal valued at up to $380 million and covering manufacturing capacity in the U.S., Europe and Japan. (Reuters)
Why Breyanzi Matters
Breyanzi is a CAR-T cell therapy used to treat lymphoma and other blood cancers. The FDA first approved it in 2021.
CAR-T therapy is a highly personalized form of cancer treatment. A patient's own immune cells are collected, genetically modified in a laboratory to recognize and attack cancer cells, and then returned to the patient. (Reuters)
Breyanzi generated approximately $1.36 billion in sales in 2025, making manufacturing capacity particularly important for BMS as demand for the therapy grows. (Reuters)
The Manufacturing Challenge
CAR-T therapies are significantly more complicated to manufacture than conventional drugs.
Each treatment is effectively connected to an individual patient because the manufacturing process starts with collecting that patient's immune cells.
The process involves:
- Collecting immune cells from the patient.
- Sending the cells for laboratory processing.
- Genetically modifying them to target cancer.
- Expanding the modified cells.
- Conducting quality testing.
- Returning the finished treatment to the patient.
This makes manufacturing consistency, speed and scalability major challenges for the industry. (Reuters)
Cellares developed the Cell Shuttle, an automated manufacturing platform intended to make cell therapy production more standardized and scalable.
BMS ultimately determined that the platform could not meet the requirements necessary for commercial-scale production of Breyanzi. (Reuters)
Impact on Cellares
The termination is a significant setback for Cellares.
The company's CEO, Fabian Gerlinghaus, had previously disclosed that Cellares had lost a large pharmaceutical customer and that the development would require the company to resize its workforce. (Reuters)
The company did not immediately respond to Reuters' request for comment on the partnership termination or potential layoffs.
Impact on Bristol Myers Squibb
For BMS, the decision underscores the difficulty of expanding manufacturing capacity for personalized cell therapies.
Breyanzi is already a major commercial product, generating $1.36 billion in sales in 2025. Ensuring reliable manufacturing capacity is therefore important as BMS seeks to expand access to the treatment. (Reuters)
The termination applies specifically to Breyanzi and its approved manufacturing process, rather than representing an exit by BMS from CAR-T therapies. (Reuters)
Why This Matters to the U.S. Healthcare Industry
CAR-T therapies have transformed treatment for certain blood cancers, but their complexity and cost remain major barriers to broader adoption.
Manufacturing is one of the biggest bottlenecks.
As more cell and gene therapies reach the market, pharmaceutical companies will need manufacturing systems capable of:
- Producing therapies consistently.
- Scaling production.
- Reducing manufacturing time.
- Maintaining strict quality standards.
- Managing patient-specific products.
- Supporting growing demand.
The BMS-Cellares breakdown illustrates how difficult that transition from clinical manufacturing to commercial-scale production can be. (Reuters)
Industry Impact
- Cell Therapy Companies: The development highlights the difficulty of building manufacturing platforms that can satisfy pharmaceutical companies' commercial requirements.
- Pharmaceutical Manufacturers: Drugmakers developing CAR-T and other personalized therapies will need increasingly sophisticated manufacturing infrastructure.
- Cancer Care: Manufacturing capacity can directly affect how quickly eligible patients can receive personalized cancer treatments.
- Healthcare Technology: Automation and standardized manufacturing platforms remain important areas of development as the cell-therapy market expands.
Looking Ahead
The industry is continuing to invest heavily in ways to make CAR-T production faster, more standardized and less expensive.
The termination of this particular partnership shows that technological promises around automated cell-therapy manufacturing still need to translate into reliable commercial production before they can support large-scale pharmaceutical launches. (Reuters)
Why This Matters
This is a significant U.S. healthcare industry story because it concerns the commercial manufacturing of an FDA-approved cancer therapy and highlights one of the biggest challenges facing the growing cell-therapy market.
The success of CAR-T therapies increasingly depends not only on clinical efficacy, but also on whether manufacturers can produce personalized treatments reliably and at scale.
Key Takeaways
- Bristol Myers Squibb ended its manufacturing partnership with Cellares for Breyanzi. (Reuters)
- BMS said Cellares' Cell Shuttle could not meet commercial-scale manufacturing requirements.
- The original 2024 agreement was worth up to $380 million.
- Breyanzi generated $1.36 billion in 2025 sales.
- The decision highlights the challenges of manufacturing personalized CAR-T therapies at commercial scale.
- Cellares' CEO previously said the loss of a major pharmaceutical customer would require the company to reduce its workforce. (Reuters)
What This Means for Healthcare Marketers
The story highlights growing demand across cell therapy manufacturing, oncology, clinical supply chains, laboratory automation and advanced-therapy infrastructure. As personalized medicines expand, companies that can demonstrate faster, more reliable and scalable manufacturing capabilities will become increasingly important to pharmaceutical developers.